High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.
about
The perils of not digging deep enough--uncovering a rare cause of acquired anemiaComparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolidDrug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia.Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center.Correlation between serum linezolid concentration and the development of thrombocytopenia.Thrombocytopenia in the intensive care unit.Linezolid-induced pure red cell aplasia in a patient with Staphylococcus epidermidis infection after allogeneic stem cell transplantation.Probable linezolid-induced thrombocytopenia in a patient with vancomycin-resistant enterococci.A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency.High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients.Thrombocytopenia in ESRD patients: epidemiology, mechanisms and interventional nephrology perspective.Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy.Risk factors for linezolid-associated thrombocytopenia in adult patients.The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.Linezolid-Associated Thrombocytopenia in Children With Renal Impairment.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.Mechanism Underlying Linezolid-induced Thrombocytopenia in a Chronic Kidney Failure Mouse Model.Effect of diuretic use on 30-day postdialysis mortality in critically ill patients receiving acute dialysis.U-curve association between timing of renal replacement therapy initiation and in-hospital mortality in postoperative acute kidney injuryLinezolid for the treatment of drug-resistant infections.Update on the safety of linezolid.Effective treatment of post-spinal fusion methicillin-resistant Staphylococcus aureus vertebral osteomyelitis with linezolid in a renal-transplant patient.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Risk factors for a low linezolid trough plasma concentration in acute infections.Reply to "Breakthrough bacteremia by linezolid-susceptible Enterococcus faecalis under linezolid treatment in a severe polytrauma patient".Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery.Current medical management of diabetic foot infections.Current pharmacotherapy options for osteomyelitis: convergences, divergences and lessons to be drawn.Clinical management of septic arthritis.Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.Nationwide epidemiology and prognosis of dialysis-requiring acute kidney injury (NEP-AKI-D) study: Design and methods.The Possible Role of Anti-Methicillin-Resistant Staphylococcus Aureus Antimicrobial Agents in Spontaneous Bacterial Peritonitis.Perioperative body weight change is associated with in-hospital mortality in cardiac surgical patients with postoperative acute kidney injury.Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial.Surveillance of listeriosis in the Tel Aviv District, Israel, 2010-2015.Is it time to revise linezolid doses in peritoneal dialysis patients? A case series.Peritoneal dialysis-related peritonitis: challenges and solutions.
P2860
Q28254062-8B69ECC6-10C8-4D18-B5E0-5F8ED8F0DCFDQ33375091-DF16F9A5-704C-41EC-AC7F-2960D15EABC3Q33389558-F6A03F72-B9DB-4808-94B2-7742130FD037Q33391635-C42EF30E-60E2-4EFC-8B7C-07388F0D2BD9Q33397069-28701C08-DBF5-48DE-A903-AA0035EE2BD2Q33399094-3E42E529-B6B6-452F-8C79-131FDE966BC7Q33400641-DB20A22C-D925-44F5-8E89-2A54E4E19EA8Q33400991-A48B299A-1AD8-4D23-9C25-CEEB44EA6580Q33403406-2243F152-4665-447A-8459-CC45903C09A6Q33407349-D881CA37-1151-4FF7-A494-EBD708A16244Q33410244-7EC6E3EB-10C8-4C51-AF05-9601146B567AQ33413274-6916ECC0-D41D-4855-96D3-6600275A20D1Q33413794-D2FC1204-6502-47DA-937C-1B31DCB393F0Q33414112-91CB81CF-20DD-4F3E-8202-35E96ECBB0C3Q33417036-05CEEE9E-006E-4FBE-83BB-9F594099D56CQ33420826-D74846D8-EC7E-43EE-86BD-B4F1D547749FQ33426216-0015ACF5-6AFA-4EAB-8DDF-362A86F34C31Q33439246-797DC659-7B2F-473F-901C-4187EC9426CAQ33440964-83EE4257-ACC7-41E0-9AE4-9CF6B12315A1Q34202707-C9BF03E6-2BC4-4927-BFEF-C3C55D3CAEDEQ34404897-C369B176-803A-4364-A7A1-F76604286511Q34894133-758D3D76-7CB6-4A36-9056-481A74684BF3Q34987632-1D9BEEF5-F4C9-4474-854D-F0E8F0810EFCQ35851305-9BF236EB-C822-438D-A6BA-23C87E0D082BQ36718474-1965114B-F0DB-4C89-B1E3-708C1D08C185Q36757691-A4AD337E-5E5B-4775-A620-9618CD44AE05Q37335675-CEA62747-683D-4DF6-9CCA-83D050672E1CQ37443215-B09D8BBE-0F8B-48A0-A1C3-96534073AB58Q37809059-8F0FD74F-F494-4722-9A48-CC8A858D3A50Q38089918-6E9DB3FF-0050-4DBC-A8FA-06F411097210Q38099554-2AB2915E-8A74-4F88-9C39-33309280A982Q38604890-705487DA-909F-4228-900D-F19D28504823Q38777085-3BCBAD35-3D3F-494D-8A1E-A3E0AFCE199DQ39468632-0D0F7E8F-2DE0-4AA4-8958-CA54416CE1AAQ40837656-1C6F39B2-EAB3-4939-8FA3-D8C2EF8049AEQ47153282-C9479347-3FF0-4322-9656-92251404C9E7Q47329892-FF064B1B-018C-4FA4-87CE-B5544F8F7829Q48298457-05A1FF79-E137-4DDC-A70B-43CD2A26C199Q53440848-D42F8D0C-353D-4A0F-84F5-0E6AD82C1ED7Q55399642-68B9DF2D-1B2A-4F40-886B-EA8628D51D5B
P2860
High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
High frequency of linezolid-as ...... with end-stage renal disease.
@ast
High frequency of linezolid-as ...... with end-stage renal disease.
@en
type
label
High frequency of linezolid-as ...... with end-stage renal disease.
@ast
High frequency of linezolid-as ...... with end-stage renal disease.
@en
prefLabel
High frequency of linezolid-as ...... with end-stage renal disease.
@ast
High frequency of linezolid-as ...... with end-stage renal disease.
@en
P2093
P2860
P50
P356
P1476
High frequency of linezolid-as ...... with end-stage renal disease.
@en
P2093
Cheng-Yi Wang
Juey-Jen Hwang
Yu-Ting Wang
P2860
P356
10.1086/498509
P407
P577
2005-11-18T00:00:00Z